Condition: Healthy Infant
Subject Age: 42 to 89 Days
Subject Gender: Male or Female
Enrollment Status: Pre-Enrolling (Summer 2020)
Compensation: $725

About the research study:

The study project will evaluate the efficacy and safety of a proposed update to the standard pneumococcal vaccine given to infants. This study is available at our Missoula location.

Who can participate?

Subjects will be healthy infants between 42 and 89 days of age.

What happens during the study?

Infants will receive 4 doses of either the study vaccine or the standard pneumococcal vaccine at approximate ages of 2 months, 4 months, 6 months, and 12 months, along with all other standard pediatric vaccines during the study period. Four blood samples will be taken - at approximate ages of 2 months, 7 months, 12 months, and 13 months. Periodic phone calls throughout the study will be made to parents to check up on infants.

How long is the study?

Approximately 12 months.